WuXi Biologics, an open-access biologics technology company, and Immune Pharmaceuticals, a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, have entered into a development and manufacturing agreement for the production of bertilimumab, Immune’s first-in-class anti-eotaxin-1 monoclonal antibody. Bertilimumab is designed to block the protein eotaxin-1, which is responsible for causing inflammation in a…